期刊文献+

肝细胞肝癌中外周血浆DNA基因甲基化检测及意义 被引量:4

Detection and Clinical Significance of Methylation of Peripheral Plasma DNA in Patients with Hepatocellular Carcinoma
原文传递
导出
摘要 目的评估外周血浆DNA甲基化检测在肝细胞肝癌(HCC)诊断中的作用,筛选血浆灵敏度及特异性高的甲基化抑癌基因。方法采用甲基化特异性PCR(MSP)检测34例经病理检查证实的HCC患者血浆及其配对癌组织中的SLIT2及DAPK基因启动子甲基化状态,并分析其与HCC临床病理特征的关系。结果 34例HCC患者癌组织中SLIT2和DAPK基因甲基化率分别为70.6%(24/34)和79.4%(27/34),相应外周血浆中SLIT2和DAPK基因甲基化率分别为44.1%(15/34)和50.0%(17/34)。血浆SLIT2和DAPK基因甲基化检测的灵敏度分别为62.5%和63.0%,特异度均为100%,阴性预测值分别为52.6%和41.2%,阳性预测值均为100%。HCC癌组织和外周血浆中SLIT2及DAPK甲基化检出率与HCC各临床病理特征无关(P>0.05)。在AFP<400μg/L患者中SLIT2和DAPK基因甲基化联合检出率达61.1%(11/18)。结论基于MSP方法,血浆中SLIT2及DAPK基因甲基化仍有较高的检出率,HCC癌组织和血浆中SLIT2及DAPK基因甲基化具有明显的一致性。血浆DNA甲基化可作为一种独立非侵入性诊断HCC的标志物,尤其对AFP阴性者可提高HCC的诊断率。HBV感染可能仅与部分抑癌基因甲基化相关。 Objective To evaluate the effect of methylation determination about the peripheral plasma DNA in diagnose of hepatocellular carcinoma (HCC) and select the highly sensitive and specific methylated cancer suppressor genes. Methods Methylation-specific PCR (MSP) was used to detect the degree of methylation about SLIT2 and DAPK genes in peripheral plasma and associated cancer tissues of 34 patients with HCC confirmed by pathology, then analyzed their relationship to clinicopathologic feature. Results The positive rate of the promoter methylation of SLIT2 and DAPK genes in cancer tissues in 34 cases were 70. 6% (24/34) and 79. 4% (27/34), while the relevant pro- moter methylation rate in plasma were 44. 1% (15/34) and 50. 0% (17/34) correspondingly. The sensitivity of detection ofDNA methylation about SLIT2 and DAPK genes in plasma was 62. 5% and 63.0%, respectively; both of the specific- ity for them were 100%. The negative predicted value was 52.6% and 41.2%, respectively; while both of the positive predicted value were 100%. There were no significant correlation between the clinicopathologic features and the meth- ylation rate in cancer tissues and plasma (P〉0.05). In plasma of patients whose AFP〈400 μg/L, the positive rate of combined detection ofDNA methylation of SLIT2 and DAPK was 61.1% (11/18). Conclusions The detection rate ofDNA methylation of SLIT2 and DAPK genes in plasma is higher, and there is a significant correlation between the DNA methylation in HCC tissue and plasma, based on MSP method. DNA methylation in plasma, as an non-invasive method, could be used to diagnose HCC, especially for the patients whose AFP is negative. HBV infection may be only associate with DNA methylation of part gene.
出处 《中国普外基础与临床杂志》 CAS 2012年第7期727-732,共6页 Chinese Journal of Bases and Clinics In General Surgery
基金 安徽省卫生厅医学科研重点课题(项目编号:2010A009)~~
关键词 肝细胞肝癌 甲基化 血浆 SLIT2 致死相关蛋白激酶 Hepatocellular carcinoma Methylation Plasma SLIT2 Death-associated protein kinase
  • 相关文献

参考文献21

  • 1Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyri-bonucleic acid as prognostic mark in non-small-cell lung cancer patients undergoing chemotherapy [J]. J Clin Oncol, 2004, 22(20): 4157-4164.
  • 2Schlechte HH, Stelzer C, Weickmann S, et al. TP53 gene in blood plasma DNA of tumor patients [J]. Ann NY Acad Sci, 2004, 1022(6): 61-69.
  • 3Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme [ J ]. CR Acad Sci Paris, 1948, 142: 241-243.
  • 4Leon SA, Shapiro B, Sklarof DM, et al. Free DNA in the se- rum of cancer patients and the efect of thempy [ J ]. Cancer Res, 1977, 37(3): 646-650.
  • 5Vaart MVD, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? [ J ]. Clinical Biochemistry, 2010, 43(1): 26-36.
  • 6黄朝晖,胡瑜,华东,程之红,谢其根,王琼瑶,王丰,周锡科,杜祥.定量PCR检测肝细胞癌患者血浆循环DNA及其临床意义[J].中国癌症杂志,2010,20(9):663-667. 被引量:9
  • 7Jackson PE, Qian GS, Friesen MD, et al. Specific p53 muta- tions detection in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry [ J]. Cancer Res, 2001, 61(1): 33-35.
  • 8Chang YC, Ho CL, Chen HHW, et al. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum [J]. BritJ Cancer, 2002, 87(12): 1449-1453.
  • 9Board RE, Williams VS, Knight L, et al. Isolation and extrac- tion of circulating tumor DNA from patients with small cell lung cancer [ J ]. Ann NY Acad Sci, 2008, 1137(8): 98-107.
  • 10Chan KC, Yeung SW, Lui WB, et al. Effects of preanalytical factors on the molecular size of cell-free DNA in blood [J]. Clin Chem, 2005, 51(4): 781-784.

二级参考文献18

  • 1任宁,钦伦秀,屠红,刘银坤,张博恒,汤钊猷.肝细胞癌病人血浆循环DNA定量分析及其临床意义[J].复旦学报(医学版),2005,32(2):134-138. 被引量:10
  • 2董慧明,刘刚,吴炅,陆劲松,罗建民,沈镇宙,邵志敏.上皮钙黏着蛋白对人炎性乳腺癌细胞系生物学特性的影响[J].中华肿瘤杂志,2006,28(1):4-7. 被引量:2
  • 3黄朝晖,华东,杜朝红,李莉华.血浆循环DNA定量检测在乳腺癌患者诊断与预后中的意义[J].中国妇幼保健,2007,22(15):2095-2097. 被引量:4
  • 4Butt AN, Swaminathan R. Overview of circulating nucleic acids in plasma/serum [ J ] . Ann N Y Acad Sci, 2008, 1137: 236-242.
  • 5Chan KC, Lo YM. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers [ J]. Br J Cancer, 2007, 96(5): 681-685.
  • 6Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients [ J ] . Cancer Lett, 2006, 243(1): 64-70.
  • 7Paci M, Maramotti S, Bellcsia E, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer [ J ]. Lung Cancer, 2009, 64(1): 92-97.
  • 8Jung M, Klotzek S, Lewandowski M, et al. Changes in concentration of DNA in serum and plasma during storage of blood samples [ J ]. Clin Chem, 2003, 49(6 Pt 1): 1028- 1029.
  • 9Gal S, Fidler C, Lo YM, et al. Quantitation of circulating DNA in the serum of breast cancer patients bv real-time PCR [ J ]. Br J Cancer, 2004, 90(6): 1211-1215.
  • 10Anker P, Mulcahy H, Chen XQ, et al. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev, 1999, 18:65-73.

共引文献13

同被引文献37

  • 1Rudd ML, Price ]C, Fogoros S, et al. A unique spectrum of somatic PIK3CA (pll0alpha) mutations within primary endometrialcarcinomas. Clin Cancer Res, 2011, 17(6): 1331-1340.
  • 2Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res, 2010, 70(14): 5674-5678.
  • 3Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin CancerRes, 2007, 13(20): 6064-6269.
  • 4Murugan AK, Hong NT, Fukui Y, et al. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol, 2008, 32(1): 101-111.
  • 5Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24(8): 1477-1480.
  • 6Dunlap J, Le C, Shulda A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat, 2010, 120(2): 409-418.
  • 7Li H, Zhu R, Wang L, et al. PIK3CA mutations mostly begin to develop in uctal carcinoma of the breast. Exp Mol Pathol, 2010, 88(1): 150-155.
  • 8MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One, 2009, 4(11): e7887.
  • 9Fumagalli D, Gavin PG, Taniyama Y, et al. A rapid, sensitive, repro- ducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer, 2010, 10: 101.
  • 10Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res, 2009, 15(16): 5049-5059.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部